Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06920004 · ClinicalTrials.gov registry record · Phase 3

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

A Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy and CIDP, sponsored by argenx.

Recruiting
Registry status
Phase 3
Development phase
218
Enrollment target
20
Study locations

NCT06920004: Recruiting Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy and CIDP, sponsored by argenx.

NCT06920004 is a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy and CIDP that is actively recruiting participants, run by argenx. The registered enrollment target is 218 participants, above the 141-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (55% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06920004, a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy and CIDP, is actively recruiting participants, sponsored by argenx.

RECRUITING
Registry status
Phase 3
Development phase
218 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emvigorate

Primary Outcome

The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

Conditions Studied

Chronic Inflammatory Demyelinating Polyneuropathy CIDP CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

  • OTHER IVIg-placebo
  • BIOLOGICAL empasiprubart
  • BIOLOGICAL IVIg
  • OTHER empasiprubart-placebo

Study Locations (20)

Other

  • Fakultni nemocnice Brno - Brno
  • Astra Kliinik - Tallinn
  • Tartu University Hospital - Tartu
  • Charité - Universitätsmedizin Berlin - Berlin
  • University General Hospital ''ATTIKON'' - General Hospital of West Attica H AGIA VARVARA - Chaïdári
  • The Barzilai University Medical Center - Ashkelon
  • Hadassah Medical Center- Ein Kerem - Jerusalem
  • The Chaim Sheba Medical Center - Tel Litwinsky
  • AUSL di Bologna - Ospedale Bellaria - Bologna
  • Aomori Prefectural Central Hospital - Aomori

Florida

  • Homestead Associates in Research Inc - Homestead
  • Visionary Investigators Network - Miami

Michigan

  • University of Michigan Hospital - Ann Arbor
  • University of Michigan Hospital - Ann Arbor

Texas

  • NeuroCarePlus - Houston
  • National Neuromuscular Research Institute - Irving

Colorado

  • Colorado Springs Neurological Associates - Colorado Springs

District of Columbia

  • MedStar Washington Hospital Center - Washington D.C.

Louisiana

  • Paradigm Health System - Slidell

Maryland

  • Erlanger Health System - Columbia

Trial Details

FieldValue
Enrollment Target 218 participants
Start Date 2025-08-22
Est. Completion 2030-09
Phase Phase 3
argenx

49 total trials

What NCT06920004 shows while recruiting

NCT06920004 is an interventional study that assigns participants to a tested intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap, above the 141-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (55% higher).

The record links to 3 conditions, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 4 interventions - of which IVIg-placebo is the first listed.

NCT06920004 names 20 study sites across 8 states, led by Other, Florida, Michigan.

Frequently Asked Questions

What is clinical trial NCT06920004 about?

NCT06920004 is a clinical study titled "A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP". The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Par...

What is the current status of trial NCT06920004?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 218 participants. The study started on 2025-08-22. Estimated completion is 2030-09.

What conditions does trial NCT06920004 study?

This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy.

What interventions are being tested in trial NCT06920004?

The interventions under investigation include: IVIg-placebo (OTHER), empasiprubart (BIOLOGICAL), IVIg (BIOLOGICAL), empasiprubart-placebo (OTHER).

Who is sponsoring clinical trial NCT06920004?

This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06920004 being conducted?

This trial has 20 study locations across Colorado, District of Columbia, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06920004's enrollment target sits among peer trials

218 3rd of 11 higher than 9 of 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Inflammatory Demyelinating Polyneuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04693858 · 218 participants · NA

    Efficacy Trial of the CALM Intervention

  • NCT05909202 · 218 participants · NA

    A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients

  • NCT06000761 · 218 participants · NA

    Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit

  • NCT06249126 · 218 participants · NA

    Primary Subtalar Arthrodesis for Calcaneal Fractures

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06920004

Source: ClinicalTrials.gov NCT06920004, the US trial registry maintained by the National Library of Medicine. NCT06920004 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.